| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 30 | 2023 | 111 | 11.690 |
Why?
|
| Adenoma | 16 | 2023 | 60 | 8.460 |
Why?
|
| Colonoscopy | 31 | 2023 | 73 | 7.960 |
Why?
|
| Colonic Polyps | 13 | 2023 | 31 | 5.780 |
Why?
|
| Early Detection of Cancer | 15 | 2023 | 102 | 3.660 |
Why?
|
| Neoplasms, Second Primary | 5 | 2022 | 37 | 2.670 |
Why?
|
| Mass Screening | 8 | 2023 | 168 | 2.110 |
Why?
|
| DNA Methylation | 5 | 2022 | 161 | 1.750 |
Why?
|
| Barrett Esophagus | 4 | 2020 | 15 | 1.650 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2022 | 13 | 1.530 |
Why?
|
| Capsule Endoscopy | 2 | 2021 | 5 | 1.370 |
Why?
|
| Humans | 55 | 2023 | 25900 | 1.310 |
Why?
|
| Long Interspersed Nucleotide Elements | 2 | 2021 | 5 | 1.260 |
Why?
|
| Esophagoscopy | 5 | 2021 | 14 | 1.090 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2018 | 39 | 1.080 |
Why?
|
| Population Surveillance | 3 | 2018 | 108 | 1.050 |
Why?
|
| Colon | 4 | 2018 | 121 | 1.050 |
Why?
|
| Adenomatous Polyps | 3 | 2017 | 4 | 1.040 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2021 | 11 | 1.040 |
Why?
|
| Middle Aged | 23 | 2021 | 8556 | 0.970 |
Why?
|
| Guideline Adherence | 2 | 2016 | 52 | 0.950 |
Why?
|
| Esophageal Neoplasms | 3 | 2020 | 48 | 0.890 |
Why?
|
| Diagnostic Errors | 2 | 2014 | 27 | 0.840 |
Why?
|
| Gastroenterology | 3 | 2019 | 9 | 0.790 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2022 | 1 | 0.780 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2022 | 2 | 0.760 |
Why?
|
| Aged | 19 | 2021 | 8658 | 0.720 |
Why?
|
| Male | 22 | 2021 | 14176 | 0.710 |
Why?
|
| Female | 22 | 2021 | 14543 | 0.700 |
Why?
|
| Intestine, Small | 1 | 2021 | 29 | 0.690 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2020 | 2 | 0.670 |
Why?
|
| Carcinoma | 2 | 2022 | 65 | 0.660 |
Why?
|
| Quality of Health Care | 2 | 2022 | 96 | 0.650 |
Why?
|
| Clinical Competence | 3 | 2016 | 201 | 0.640 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 139 | 0.640 |
Why?
|
| No-Show Patients | 1 | 2019 | 1 | 0.620 |
Why?
|
| Censuses | 1 | 2019 | 9 | 0.620 |
Why?
|
| Poverty Areas | 1 | 2019 | 10 | 0.620 |
Why?
|
| Retrospective Studies | 10 | 2023 | 3342 | 0.570 |
Why?
|
| Esophagus | 2 | 2021 | 61 | 0.550 |
Why?
|
| Pancreatic Neoplasms | 2 | 2020 | 90 | 0.550 |
Why?
|
| Residence Characteristics | 1 | 2019 | 206 | 0.550 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 25 | 0.540 |
Why?
|
| Cecum | 1 | 2016 | 14 | 0.520 |
Why?
|
| Lymphoid Tissue | 1 | 2016 | 10 | 0.520 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 24 | 0.510 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 41 | 0.490 |
Why?
|
| Biopsy | 5 | 2021 | 189 | 0.490 |
Why?
|
| Colorectal Surgery | 1 | 2015 | 1 | 0.470 |
Why?
|
| Colonic Neoplasms | 3 | 2022 | 53 | 0.470 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 24 | 0.470 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 186 | 0.460 |
Why?
|
| Hyperplasia | 3 | 2021 | 18 | 0.450 |
Why?
|
| Risk Factors | 5 | 2021 | 2173 | 0.450 |
Why?
|
| Patient Compliance | 1 | 2015 | 145 | 0.430 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 103 | 0.430 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 12 | 0.430 |
Why?
|
| Intestines | 1 | 2014 | 84 | 0.420 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 251 | 0.380 |
Why?
|
| Prospective Studies | 5 | 2023 | 1686 | 0.370 |
Why?
|
| Intestinal Mucosa | 4 | 2022 | 171 | 0.340 |
Why?
|
| Cohort Studies | 5 | 2018 | 1815 | 0.340 |
Why?
|
| Colectomy | 1 | 2010 | 16 | 0.340 |
Why?
|
| Colitis, Ulcerative | 1 | 2010 | 53 | 0.330 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 339 | 0.330 |
Why?
|
| United States | 4 | 2020 | 1935 | 0.310 |
Why?
|
| Chi-Square Distribution | 3 | 2015 | 127 | 0.300 |
Why?
|
| Logistic Models | 3 | 2015 | 368 | 0.280 |
Why?
|
| Incidence | 3 | 2019 | 720 | 0.280 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 26 | 0.270 |
Why?
|
| Graft vs Host Disease | 1 | 2007 | 32 | 0.270 |
Why?
|
| Area Under Curve | 2 | 2019 | 61 | 0.260 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2023 | 3 | 0.260 |
Why?
|
| Treatment Outcome | 4 | 2023 | 3339 | 0.240 |
Why?
|
| Risk Assessment | 4 | 2020 | 553 | 0.230 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 125 | 0.230 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 830 | 0.220 |
Why?
|
| Intestinal Polyposis | 1 | 2023 | 2 | 0.220 |
Why?
|
| Hyperthermia, Induced | 1 | 2023 | 9 | 0.220 |
Why?
|
| Surgical Instruments | 1 | 2023 | 20 | 0.200 |
Why?
|
| Adult | 6 | 2020 | 7517 | 0.200 |
Why?
|
| Prognosis | 4 | 2018 | 695 | 0.200 |
Why?
|
| Benchmarking | 1 | 2022 | 31 | 0.190 |
Why?
|
| Esophageal pH Monitoring | 1 | 2021 | 2 | 0.190 |
Why?
|
| Zenker Diverticulum | 1 | 2021 | 1 | 0.180 |
Why?
|
| Endosonography | 2 | 2020 | 7 | 0.180 |
Why?
|
| Gastrointestinal Transit | 1 | 2021 | 12 | 0.180 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 22 | 0.180 |
Why?
|
| MicroRNAs | 1 | 2022 | 75 | 0.180 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 22 | 0.180 |
Why?
|
| Pancreatitis, Chronic | 1 | 2020 | 1 | 0.170 |
Why?
|
| Pancreatic Cyst | 1 | 2020 | 2 | 0.170 |
Why?
|
| Observer Variation | 1 | 2021 | 95 | 0.170 |
Why?
|
| Ikaros Transcription Factor | 1 | 2020 | 1 | 0.170 |
Why?
|
| Transaminases | 1 | 2020 | 6 | 0.170 |
Why?
|
| Circulating Tumor DNA | 1 | 2020 | 6 | 0.170 |
Why?
|
| Gastroparesis | 1 | 2020 | 3 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2021 | 200 | 0.170 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4633 | 0.170 |
Why?
|
| Magnets | 1 | 2020 | 3 | 0.170 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 6 | 0.160 |
Why?
|
| Epithelial Cells | 2 | 2013 | 92 | 0.160 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 52 | 0.160 |
Why?
|
| Databases, Factual | 1 | 2021 | 328 | 0.160 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 11 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2020 | 130 | 0.150 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 619 | 0.150 |
Why?
|
| ROC Curve | 1 | 2019 | 131 | 0.150 |
Why?
|
| Forecasting | 1 | 2019 | 91 | 0.150 |
Why?
|
| Simulation Training | 1 | 2019 | 38 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 3 | 0.150 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 12 | 0.150 |
Why?
|
| Genetic Testing | 1 | 2018 | 54 | 0.150 |
Why?
|
| Colonoscopes | 1 | 2018 | 1 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2018 | 87 | 0.140 |
Why?
|
| Sex Factors | 2 | 2018 | 453 | 0.140 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 84 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 56 | 0.130 |
Why?
|
| CpG Islands | 1 | 2017 | 54 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 25 | 0.130 |
Why?
|
| Gastroenterologists | 1 | 2016 | 3 | 0.130 |
Why?
|
| Age Factors | 2 | 2018 | 738 | 0.130 |
Why?
|
| Portal Vein | 1 | 2017 | 45 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 85 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 1 | 2017 | 66 | 0.130 |
Why?
|
| Documentation | 1 | 2016 | 21 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 66 | 0.120 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2015 | 1 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 102 | 0.120 |
Why?
|
| Staff Development | 1 | 2015 | 18 | 0.120 |
Why?
|
| Nursing Staff, Hospital | 1 | 2015 | 25 | 0.120 |
Why?
|
| Hospitals, Community | 1 | 2015 | 14 | 0.120 |
Why?
|
| Rectal Neoplasms | 1 | 2015 | 15 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2013 | 567 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 450 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 847 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2015 | 248 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 421 | 0.110 |
Why?
|
| Microsatellite Instability | 1 | 2014 | 12 | 0.110 |
Why?
|
| Metaplasia | 1 | 2014 | 7 | 0.110 |
Why?
|
| Stomach | 1 | 2014 | 13 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 76 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2016 | 206 | 0.100 |
Why?
|
| Mast Cells | 1 | 2013 | 17 | 0.100 |
Why?
|
| Colitis | 1 | 2013 | 31 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 44 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 51 | 0.100 |
Why?
|
| Time Factors | 1 | 2016 | 1376 | 0.100 |
Why?
|
| Macrophages | 1 | 2013 | 108 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 631 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 116 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 1708 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 355 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2007 | 17 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2007 | 44 | 0.070 |
Why?
|
| Diarrhea | 1 | 2007 | 31 | 0.070 |
Why?
|
| Acute Disease | 1 | 2007 | 165 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 96 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2007 | 55 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 110 | 0.060 |
Why?
|
| Apoptosis | 1 | 2007 | 204 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1324 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 260 | 0.060 |
Why?
|
| Reoperation | 1 | 2010 | 912 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 87 | 0.060 |
Why?
|
| Fecal Incontinence | 1 | 2005 | 2 | 0.060 |
Why?
|
| Geriatric Assessment | 1 | 2005 | 203 | 0.050 |
Why?
|
| Occult Blood | 1 | 2023 | 3 | 0.050 |
Why?
|
| Feces | 1 | 2023 | 100 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2022 | 25 | 0.050 |
Why?
|
| Manometry | 1 | 2021 | 15 | 0.050 |
Why?
|
| Endoscopes | 1 | 2021 | 8 | 0.050 |
Why?
|
| Pyloromyotomy | 1 | 2020 | 1 | 0.040 |
Why?
|
| Pylorus | 1 | 2020 | 1 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 5 | 0.040 |
Why?
|
| Gastric Emptying | 1 | 2020 | 12 | 0.040 |
Why?
|
| Gastroplasty | 1 | 2020 | 16 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 61 | 0.040 |
Why?
|
| Inventions | 1 | 2019 | 2 | 0.040 |
Why?
|
| Biomedical Technology | 1 | 2019 | 4 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 15 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 43 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 23 | 0.040 |
Why?
|
| Watchful Waiting | 1 | 2019 | 9 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 35 | 0.040 |
Why?
|
| Gastric Bypass | 1 | 2020 | 69 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 2019 | 37 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 193 | 0.040 |
Why?
|
| Virtual Reality | 1 | 2019 | 13 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 82 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2020 | 94 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2019 | 118 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 20 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 88 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 101 | 0.040 |
Why?
|
| Videotape Recording | 1 | 2018 | 18 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 196 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 313 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 110 | 0.030 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2017 | 1 | 0.030 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 1 | 0.030 |
Why?
|
| Portal Pressure | 1 | 2017 | 4 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 5 | 0.030 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2017 | 4 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2017 | 13 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 646 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 563 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 58 | 0.030 |
Why?
|
| Focus Groups | 1 | 2015 | 83 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2015 | 54 | 0.030 |
Why?
|
| Alcoholism | 1 | 2015 | 67 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 13 | 0.030 |
Why?
|
| ras Proteins | 1 | 2014 | 10 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 22 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 32 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 83 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 95 | 0.030 |
Why?
|
| Piroxicam | 1 | 2013 | 5 | 0.030 |
Why?
|
| Tryptases | 1 | 2013 | 4 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2013 | 8 | 0.030 |
Why?
|
| Chromones | 1 | 2013 | 9 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 2013 | 6 | 0.030 |
Why?
|
| Morpholines | 1 | 2013 | 13 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 18 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 26 | 0.030 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2013 | 26 | 0.030 |
Why?
|
| Mutation | 1 | 2014 | 319 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 80 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 177 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 246 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 304 | 0.020 |
Why?
|
| Rectum | 1 | 2011 | 48 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 97 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 443 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 431 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 1390 | 0.020 |
Why?
|
| Animals | 1 | 2013 | 3504 | 0.010 |
Why?
|
| Causality | 1 | 2005 | 53 | 0.010 |
Why?
|
| Psychotropic Drugs | 1 | 2005 | 26 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2005 | 103 | 0.010 |
Why?
|
| Health Surveys | 1 | 2005 | 85 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 120 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 457 | 0.010 |
Why?
|
| Chicago | 1 | 2005 | 906 | 0.010 |
Why?
|
| Stroke | 1 | 2005 | 262 | 0.010 |
Why?
|